Skip to main content

TLRY

Stock

TLRY

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

TLRY Price
Price Chart

Forward-looking statistics

Beta
1.43
Risk
73.08%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees1K
Market cap$1.5B

Fundamentals

Enterprise value$480.9M
Revenue$826.7M
Revenue per employee
Profit margin-114.40%
Debt to equity12.73

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.10
Dividend per share
Revenue per share$0.98
Avg trading volume (30 day)$16M
Avg trading volume (10 day)$15M
Put-call ratio

Macro factor sensitivity

Growth-1.2
Credit+9.6
Liquidity+2.0
Inflation-4.3
Commodities-0.4
Interest Rates-4.9

Valuation

Dividend yield0.00%
PEG Ratio-7.70
Price to sales0.67
P/E Ratio-7.70
Enterprise Value to Revenue0.58
Price to book0.19

Upcoming events

Next earnings dayApril 8, 2025
Next dividend day
Ex. dividend day

News

Tilray Brands, Inc. (TLRY) Declines More Than Market: Some Information for Investors

In the closing of the recent trading day, Tilray Brands, Inc. (TLRY) stood at $0.58, denoting a -8.88% move from the preceding trading day.

Zacks Investment Research (July 11, 2025)
Cannabis/Beer Company Tilray Outlines Plan To Reduce Its Beverage Portfolio, Reports Mixed Q2 Earnings

On Friday, Tilray Brands, Inc's. TLRY second-quarter net revenue increased 9% year-over-year to $210.95 million, missing the consensus of $216.91 million.

Benzinga (January 10, 2025)
We think Trump may support cannabis legalization, says Tilray CEO Irwin Simon

Irwin Simon, Tilray CEO, joins CNBC's 'Money Movers' to discuss outlooks on the cannabis industry, the year ahead for Tilray, and more.

CNBC Television (January 2, 2025)
We need to make beer in the US, Tilray CEO says

Tilray CEO Irwin Simon discusses the impact of President-elect Donald Trump's tariffs proposal on the business on 'The Claman Countdown.'

Fox Business (December 16, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free